Seminario web
The growing role of real-world evidence
As expectations to demonstrate value intensify, Real-World Evidence (RWE) is moving from a supporting role to a central component of regulatory reviews and Health Technology Assessments (HTAs) across agencies, including EMA, NICE, HAS, G-BA, FDA, and Canada’s Drug Agency. Watch the webinar recording to recap the discussion with our experts on how high-quality RWE addresses JCAs, refines comparators and PICOs, and why oncology leads through integrated registries and EHRs.
Key highlights
- Understand how regulators and HTA bodies are increasingly incorporating RWE into decision-making and where it adds the most value.
- Learn how JCAs in Europe are changing expectations for RWE to address comparators, patient populations, outcomes, and PICOs.
- Explore why oncology is leading the way in RWE use through cancer registries and integrated claims data across Europe.
- Recognize the growing role of large-scale EHR databases, especially in the U.S., in generating robust, longitudinal real-world evidence.
- Identify practical principles for ensuring RWE completeness, accuracy, and reproducibility to build credibility with agencies and HTA bodies.
Moderator:
Zack Bridges, Director, Client Relations, Cencora
Speakers:
Henri Leleu, Lead, Integrated Evidence Planning, Cencora
Dana Stafkey, Vice President, Real-world evidence, Cencora
Access the recording to learn more and stay ahead in an evolving global healthcare environment
Pardot Form
